GlaxoSmithKline (GSK) Stock Forecast & Price Target

Compare

5,174 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

GSK Analyst Ratings

Moderate Sell

1 Buy

2 Hold

3 Sell

Based on 6 analysts giving stock ratings to

GlaxoSmithKline

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

GSK Stock 12 Month Forecast

Average Price Target

$38.70

▼(-22.94% Downside)

Based on 6 Wall Street analysts offering 12 month price targets for GlaxoSmithKline in the last 3 months. The average price target is $38.70 with a high forecast of $55.60 and a low forecast of $20.11. The average price target represents a -22.94% change from the last price of $50.22.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"$19","56":"$56","28.25":"$28.3","37.5":"$37.5","46.75":"$46.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":55.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$55.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$38.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.1105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.11</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,28.25,37.5,46.75,56],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.04,49.54461538461538,50.04923076923077,50.55384615384615,51.058461538461536,51.56307692307692,52.06769230769231,52.572307692307696,53.07692307692308,53.581538461538464,54.08615384615385,54.59076923076923,55.09538461538462,{"y":55.6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.04,48.244615384615386,47.449230769230766,46.65384615384615,45.85846153846154,45.06307692307692,44.26769230769231,43.472307692307695,42.676923076923075,41.88153846153846,41.08615384615385,40.29076923076923,39.495384615384616,{"y":38.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.04,46.814653846153846,44.58930769230769,42.36396153846154,40.138615384615385,37.91326923076923,35.68792307692307,33.462576923076924,31.237230769230766,29.011884615384613,26.78653846153846,24.561192307692306,22.33584615384615,{"y":20.1105,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":32.438,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.829,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":36.449,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.721,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.574,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.86,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":38.202,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":36.839,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.332,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.122,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.461,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.19,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.04,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$55.60

Average Price Target$38.70

Lowest Price Target$20.11

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Michael Leuchten

Jefferies

$55.6

Buy

10.71%

Upside

Reiterated

01/07/26

GlaxoSmithKline (GSK) Receives a Buy from Jefferies

Emily Field

Barclays

Sell

―

Downgraded

01/06/26

GSK downgraded to Underweight from Equal Weight at BarclaysGSK downgraded to Underweight from Equal Weight at Barclays

Unknown Analyst

Berenberg Bank

Not Ranked

Berenberg Bank

$43

Hold

-14.38%

Downside

Reiterated

01/06/26

Berenberg Bank Sticks to Its Hold Rating for GlaxoSmithKline (GSK)

Steve Scala

TD Cowen

$52

Hold

3.54%

Upside

Reiterated

12/18/25

TD Cowen Remains a Hold on GlaxoSmithKline (GSK)

Unknown Analyst

HSBC

Not Ranked

HSBC

$16.09→$20.11

Sell

-59.96%

Downside

Reiterated

12/02/25

Sachin Jain

Bank of America Securities

$19.23→$22.79

Sell

-54.62%

Downside

Reiterated

10/29/25

Peter Verdult

Exane BNP Paribas

$35.25

Hold

-29.81%

Downside

Initiated

04/15/25

GSK initiated with a Neutral at BNP Paribas ExaneGSK initiated with a Neutral at BNP Paribas Exane

Wan Nurhayati

CFRA

$42→$40

Hold

-20.35%

Downside

Reiterated

02/05/25

GlaxoSmithKline (GSK) PT Lowered to $40 at CFRACFRA analyst Wan Nurhayati lowered the price target on GlaxoSmithKline (NYSE: GSK) to $40.00 (from $42.00) while maintaining a Hold rating.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Michael Leuchten

Jefferies

$55.6

Buy

10.71%

Upside

Reiterated

01/07/26

GlaxoSmithKline (GSK) Receives a Buy from Jefferies

Emily Field

Barclays

Sell

―

Downgraded

01/06/26

GSK downgraded to Underweight from Equal Weight at BarclaysGSK downgraded to Underweight from Equal Weight at Barclays

Unknown Analyst

Berenberg Bank

Not Ranked

Berenberg Bank

$43

Hold

-14.38%

Downside

Reiterated

01/06/26

Berenberg Bank Sticks to Its Hold Rating for GlaxoSmithKline (GSK)

Steve Scala

TD Cowen

$52

Hold

3.54%

Upside

Reiterated

12/18/25

TD Cowen Remains a Hold on GlaxoSmithKline (GSK)

Unknown Analyst

HSBC

Not Ranked

HSBC

$16.09→$20.11

Sell

-59.96%

Downside

Reiterated

12/02/25

Sachin Jain

Bank of America Securities

$19.23→$22.79

Sell

-54.62%

Downside

Reiterated

10/29/25

Peter Verdult

Exane BNP Paribas

$35.25

Hold

-29.81%

Downside

Initiated

04/15/25

GSK initiated with a Neutral at BNP Paribas ExaneGSK initiated with a Neutral at BNP Paribas Exane

Wan Nurhayati

CFRA

$42→$40

Hold

-20.35%

Downside

Reiterated

02/05/25

GlaxoSmithKline (GSK) PT Lowered to $40 at CFRACFRA analyst Wan Nurhayati lowered the price target on GlaxoSmithKline (NYSE: GSK) to $40.00 (from $42.00) while maintaining a Hold rating.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering GlaxoSmithKline

1 Month

xxx

Success Rate

2/2 ratings generated profit

Average Return

+2.20%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +2.20% per trade.

3 Months

xxx

Success Rate

2/2 ratings generated profit

Average Return

+7.50%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +7.50% per trade.

1 Year

OpenAI Drug Manufacturers - GeneralTipRanks - OpenAI

Success Rate

2/2 ratings generated profit

Average Return

+7.50%

reiterated a buy rating 2 months ago

Copying OpenAI Drug Manufacturers - General's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +7.50% per trade.

2 Years

xxx

Success Rate

2/2 ratings generated profit

Average Return

+7.50%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +7.50% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GSK Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, GSK has received 2 Buy Ratings, 3 Hold Ratings, and 2 Sell Ratings. GSK average Analyst price target in the past 3 months is 38.70.

Each month's total comprises the sum of three months' worth of ratings.

GSK Financial Forecast

GSK Earnings Forecast

Next quarter’s earnings estimate for GSK is $0.66 with a range of $0.60 to $0.79. The previous quarter’s EPS was $1.46. GSK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year GSK has Performed in-line its overall industry.

GSK Sales Forecast

Next quarter’s sales forecast for GSK is $11.28B with a range of $10.99B to $11.51B. The previous quarter’s sales results were $11.52B. GSK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year GSK has Performed in-line its overall industry.

GSK Stock Forecast FAQ

What is GSK’s average 12-month price target, according to analysts?

Based on analyst ratings, GlaxoSmithKline’s 12-month average price target is 38.70.

What is GSK’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for GSK, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is GSK a Buy, Sell or Hold?

GlaxoSmithKline has a consensus rating of Moderate Sell which is based on 1 buy ratings, 2 hold ratings and 3 sell ratings.

What is GlaxoSmithKline’s price target?

The average price target for GlaxoSmithKline is 38.70. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $55.60 ,the lowest forecast is $20.11. The average price target represents -22.94% Decrease from the current price of $50.22.

What do analysts say about GlaxoSmithKline?

GlaxoSmithKline’s analyst rating consensus is a Moderate Sell. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of GSK?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

GlaxoSmithKline (GSK) Stock Forecast & Price Target

GSK Analyst Ratings

GSK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering GlaxoSmithKline

GSK Analyst Recommendation Trends

GSK Financial Forecast

GSK Earnings Forecast

GSK Sales Forecast

GSK Stock Forecast FAQ

Detailed List of Analyst Forecasts